Sydney Chen

Dr. Chen is currently Director of Quality Control & Bioanalytics at Solstice Neurosciences. Her seventeen plus years of biopharmaceutical industry experience encompassed discovery and development of diagnostic markers and therapeutic drugs, assay development as well as quality management. In her current role, Dr. Chen is responsible for assay analytical development and product quality control of company’sprotein drug. She is also the CMC lead for regulatory correspondences for product’sworldwide commercial market. Prior joining Solstice, she has made significant contributions at various roles for Telik, diaDexus, GeneMed and Bristol Myers Squibb. She received her doctoral degree in Biochemistry and Molecular Biology from Rutgers, State University of New Jersey. Being a long time CBA volunteer, Dr. Chen has served in various capacities in the past, including two terms of vice president in 1999 and 2009.